Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Woronow

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|May 1, 2024
Prolonged Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Postmarketing CasesDaniel Woronow, Christine Chamberlain, Monika Houstoun, et al.
Vascular Medicine (London, England)|April 12, 2021
Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literatureConnie Cheng, Michelle Nadeau Nguyen, Afrouz Nayernama, et al.
BMJ Open|April 17, 2023
Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort studyEfe Eworuke, Mayura Shinde, Laura Hou, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|May 1, 2024
Prolonged Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Postmarketing CasesDaniel Woronow, Christine Chamberlain, Monika Houstoun, et al.
Vascular Medicine (London, England)|April 12, 2021
Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literatureConnie Cheng, Michelle Nadeau Nguyen, Afrouz Nayernama, et al.
BMJ Open|April 17, 2023
Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort studyEfe Eworuke, Mayura Shinde, Laura Hou, et al.
Pageof 1